Progress and introduction
of main products
LQ043H is an inhaled VHH antibody formulation targeting TSLP (thymic stromal lymphopoietin), independently developed by Novamab, intended for the treatment of moderate to severe asthma in both non-eosinophilic and eosinophilic phenotypes. Recent clinical studies have shown that TSLP plays a key role in asthma pathogenesis, and its inhibition has become an important strategy for treating broad-spectrum asthma.
Broad-Spectrum Indication Coverage: By targeting the upstream inflammatory cytokine TSLP, it addresses both T2-high and T2-low asthma patients, expanding the potential patient population.
Pulmonary Targeted Delivery with Rapid Onset: The drug is delivered to the lungs via a portable nebulizer device, effectively increasing local exposure, reducing systemic toxicity, and offering good safety and patient adherence.
High-Yield Expression Platform: Based on the Pichia pastoris expression system, protein yields can reach 20 g/L, providing cost advantages and scalability for large-scale production.
Preliminary Validation of Favorable Safety: The Phase Ia clinical study (in healthy subjects) has been completed; all dose groups (1 mg, 4 mg, 12 mg, 24 mg, 40 mg) demonstrated good safety, tolerability, and low immunogenicity.
Thymic stromal lymphopoietin (TSLP) is a short-chain, four–α-helix–bundle type I cytokine in the interleukin-2 (IL-2) family. It induces monocytes to release T-cell–attracting chemokines, promotes dendritic cell maturation, and drives the release of downstream type 2 cytokines (including IL-4, IL-5, and IL-13), thereby enhancing IgE production, mast cell activation, mucus secretion, and airway hyperresponsiveness. TSLP also activates multiple cell types involved in non-type-2–driven inflammation. As a critical mediator across all asthma phenotypes, targeting TSLP or its signaling pathway with antibody therapeutics is considered an effective treatment strategy. The LQ043H VHH antibody effectively inhibits TSLP binding to TSLPR, blocks TSLP–TSLPR/IL-7Rα–mediated signaling, and thereby mitigates eosinophilic (both allergic and nonallergic) inflammation, non-eosinophilic inflammation, and structural remodeling in the airway, ultimately relieving asthma symptoms.
Moderate and severe asthma、COPD
Nebulized Inhalation
